BRPI0510142A - compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina - Google Patents

compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina

Info

Publication number
BRPI0510142A
BRPI0510142A BRPI0510142-5A BRPI0510142A BRPI0510142A BR PI0510142 A BRPI0510142 A BR PI0510142A BR PI0510142 A BRPI0510142 A BR PI0510142A BR PI0510142 A BRPI0510142 A BR PI0510142A
Authority
BR
Brazil
Prior art keywords
transthyretin
compounds
compositions
methods
duplication
Prior art date
Application number
BRPI0510142-5A
Other languages
English (en)
Inventor
Richard Labaudiniere
Original Assignee
Foldrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foldrx Pharmaceuticals Inc filed Critical Foldrx Pharmaceuticals Inc
Publication of BRPI0510142A publication Critical patent/BRPI0510142A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

COMPOSTOS, COMPOSIçõES E MéTODOS PARA ESTABILIZAR A TRANSTIRETINA E INIBIR A DUPLICAçãO DEFEITUOSA DA TRANSTIRETINA.Compostos, composições e métodos são fornecidos para estabilizar a transtiretina e para tratar, prevenir, ou melhorar um ou mais sintomas de doenças mediadas pela transtiretina. Em uma forma de realização, os compostos são benzoxazóis e compostos relacionados.
BRPI0510142-5A 2004-05-20 2005-05-20 compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina BRPI0510142A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57372004P 2004-05-20 2004-05-20
PCT/US2005/017612 WO2005113523A1 (en) 2004-05-20 2005-05-20 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Publications (1)

Publication Number Publication Date
BRPI0510142A true BRPI0510142A (pt) 2007-10-02

Family

ID=34970266

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0510142-5A BRPI0510142A (pt) 2004-05-20 2005-05-20 compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina
BRPI0510033-0A BRPI0510033A (pt) 2004-05-20 2005-05-20 estabilização de transtiretina

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0510033-0A BRPI0510033A (pt) 2004-05-20 2005-05-20 estabilização de transtiretina

Country Status (12)

Country Link
US (5) US20050261365A1 (pt)
EP (3) EP1768968A1 (pt)
JP (2) JP2007538103A (pt)
KR (2) KR20070032700A (pt)
CN (2) CN101198598A (pt)
AU (2) AU2005245470A1 (pt)
BR (2) BRPI0510142A (pt)
CA (2) CA2566923A1 (pt)
MX (1) MXPA06013381A (pt)
RU (1) RU2371440C2 (pt)
WO (3) WO2005112913A1 (pt)
ZA (1) ZA200610417B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4865958B2 (ja) 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
DE60323155D1 (de) * 2002-12-19 2008-10-02 Scripps Research Inst Von transthyretin und zur hemmung von transthyretin-fehlfaltung
CN101198598A (zh) * 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
JP2010509992A (ja) * 2006-11-17 2010-04-02 任天堂株式会社 ビデオゲームプログラムのダウンロードシステムおよびダウンロード方法
BR112012014022A2 (pt) 2009-12-11 2017-04-04 Genecode As composto, composição, dispositivo médico e método ex vivo para modulação do crescimento de um neurônico
KR101835386B1 (ko) 2010-04-29 2018-03-08 아이오니스 파마수티컬즈, 인코포레이티드 트랜스티레틴 발현의 조절
WO2012061785A2 (en) 2010-11-05 2012-05-10 Brandeis University Ice inhibiting compounds and uses thereof
BR112014005810A2 (pt) 2011-09-16 2017-03-28 Pfizer formas sólidas de um inibidor da dissociação de transtirretina
MX347784B (es) 2011-10-24 2017-05-12 Som Innovation Biotech S L Nueva terapia para la amiloidosis asociada a transtiretina.
US9399775B2 (en) * 2011-11-18 2016-07-26 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
WO2014124334A2 (en) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
US9932319B2 (en) 2013-05-28 2018-04-03 Empire Technology Development Llc Antioxidant humic acid derivatives and methods of preparation and use
EP3004069B1 (en) 2013-05-28 2017-04-19 Empire Technology Development LLC Humic acid derivatives and methods of preparation and use
WO2014209369A1 (en) 2013-06-28 2014-12-31 Empire Technology Development Llc Edible plasticizers for food and food packaging films
EP3221299A1 (en) 2014-11-21 2017-09-27 BSIM2 Biomolecular Simulations Lda. 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
WO2016203402A1 (en) 2015-06-15 2016-12-22 Bsim2 – Biomolecular Simulations Lda Bis-furan derivatives as transthyretin (ttr) stabilizers and amyloid inhibitors for the treatment of familial amyloid polyneuropathy (fap)
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
EP3833344A4 (en) * 2018-08-06 2022-07-06 The Board of Trustees of the Leland Stanford Junior University 2-ARYLBENZIMIDAZOLE AS PPARGC1A ACTIVATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CA3141998A1 (en) * 2019-05-31 2020-12-03 Plex Pharmaceuticals, Inc. Pharmacological agents for treating protein aggregation diseases of the eye
WO2021019448A1 (en) * 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
MX2022009025A (es) 2020-01-28 2022-10-07 Protego Biopharma Inc Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina.
WO2022112919A1 (en) * 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN112362432B (zh) * 2021-01-12 2021-04-09 广州科方生物技术股份有限公司 一种通用于血清中tt3和tt4的解离剂及其制备方法

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE274490C (pt) *
DE602336C (de) * 1933-03-09 1934-09-06 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Kuepenfarbstoffen der Anthrachinonreihe
FR769405A (fr) * 1933-03-09 1934-08-25 Ig Farbenindustrie Ag Procédé de production de colorants pour cuve
US3443943A (en) * 1967-07-24 1969-05-13 Polaroid Corp Photographic products and processes employing ring - closing 2 - equivalent silver halide developing agents
US3551443A (en) * 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE29608E (en) 1972-05-18 1978-04-11 Lilly Industries Limited Benzoxazole derivatives
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
DE2314238A1 (de) * 1973-03-22 1974-09-26 Henkel & Cie Gmbh Neue 2-(tetrazol-5'-yl)-benzoxazole, deren herstellung sowie verwendung als entzuendungshemmer in kosmetischen praeparationen
DE2619547A1 (de) 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4416892A (en) 1981-04-23 1983-11-22 Lilly Industries Limited Method of treating hypersensitivity disease with benzoxazole derivatives
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
DE3916729A1 (de) * 1989-05-23 1990-12-06 Behringwerke Ag Fluorogene verbindungen und ihre verwendung
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
JPH03258770A (ja) * 1990-03-08 1991-11-19 Tanabe Seiyaku Co Ltd ベンズアゾール誘導体、その製法及びその合成中間体
DE4011106A1 (de) * 1990-04-06 1991-10-10 Bayer Ag Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5254692A (en) 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
CA2051518A1 (en) 1990-10-01 1992-04-02 Robert J. Perry Synthesis of heterocyclic compounds
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
JP3021028B2 (ja) 1990-11-19 2000-03-15 株式会社日本化学工業所 アゾール型カチオン染料
CH681806A5 (pt) 1991-03-19 1993-05-28 Ciba Geigy Ag
JPH0517458A (ja) 1991-07-04 1993-01-26 Idemitsu Kosan Co Ltd 芳香族化合物とその製造方法
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JPH0673050A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ヘテロ環化合物
JPH0673051A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ベンズアゾール誘導体
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH06239849A (ja) 1993-02-16 1994-08-30 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法及び表示装置
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
JP3243887B2 (ja) 1993-05-28 2002-01-07 三菱化学株式会社 有機電界発光素子
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
JPH0797379A (ja) 1993-09-06 1995-04-11 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5441946A (en) * 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
CA2202058C (en) * 1994-10-07 2007-11-06 Hidenori Ohki Cyclic hexapeptides having antibiotic activity
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US5837390A (en) 1995-05-10 1998-11-17 Sony Corporation Metal complex, method for producing the same and optical device
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
JP3861930B2 (ja) 1995-12-15 2006-12-27 ソニー株式会社 金属複核錯体、その製造方法及び光学的素子
JPH09227576A (ja) 1996-02-23 1997-09-02 Sony Corp 金属複核錯体、その製造方法及び光学的素子
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
JP3760508B2 (ja) 1996-06-10 2006-03-29 東洋インキ製造株式会社 有機エレクトロルミネッセンス素子材料およびそれを用いた有機エレクトロルミネッセンス素子
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
CN1233954A (zh) 1996-10-01 1999-11-03 西马实验室股份有限公司 掩盖味道的微胶囊组合物及其制备方法
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
FR2767527B1 (fr) * 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
KR100719273B1 (ko) 1997-10-28 2007-05-18 반도 카가쿠 가부시키가이샤 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법
JP3279974B2 (ja) 1997-12-03 2002-04-30 帝人株式会社 帯電防止性ポリエステルフィルム
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
ATE244241T1 (de) 1998-02-04 2003-07-15 Univ Texas Hemmung der menschlichen telomerase durch g- quadruplex interaktionverbindung
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6107491A (en) * 1998-07-20 2000-08-22 Ciba Specialty Chemicals Corporation Polymerizable diketopyrrolopyrroles
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
JP2000100569A (ja) 1998-09-22 2000-04-07 Toray Ind Inc 発光素子
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
JP2001055332A (ja) 1999-06-07 2001-02-27 Saitama Daiichi Seiyaku Kk 芳香族アミジン誘導体類含有のイオントフォレ−シス用製剤
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
CN1356988A (zh) 1999-06-18 2002-07-03 拜尔公司 苯氧基氟代嘧啶类化合物
JP2001064166A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 貼付剤
JP2001064205A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 製剤組成物
WO2001012183A1 (en) 1999-08-16 2001-02-22 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
JP2001242165A (ja) 2000-02-25 2001-09-07 Dai Ichi Seiyaku Co Ltd 採血用試薬
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP3938689B2 (ja) * 2000-03-16 2007-06-27 エフ．ホフマン−ラ ロシュ アーゲー Ｉｐアンタゴニストとしてのカルボン酸誘導体
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
JP3945123B2 (ja) 2000-04-10 2007-07-18 三菱化学株式会社 有機電界発光素子
JP2001301329A (ja) 2000-04-20 2001-10-31 Mitsubishi Chemicals Corp 光学記録媒体
JP2002003368A (ja) 2000-06-23 2002-01-09 Saitama Daiichi Seiyaku Kk 経皮吸収又は経粘膜吸収用の製剤
HU230581B1 (hu) 2000-08-24 2017-01-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében
MXPA03003829A (es) * 2000-11-04 2003-07-28 Aventis Pharma Ltd Acidos alcanoicos substituidos.
JP2004515496A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
US7045539B2 (en) * 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
US20020160394A1 (en) 2001-01-24 2002-10-31 Bayer Corporation Regulation of transthyretin to treat obesity
GB0118357D0 (en) * 2001-07-27 2001-09-19 Syngenta Ltd Chemical compounds
WO2003020698A2 (en) 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US6602619B2 (en) * 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
US20060106074A1 (en) 2001-11-28 2006-05-18 Peter Bernstein Er-b-selective ligands
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
US7094801B2 (en) * 2001-12-19 2006-08-22 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
EP1487843A4 (en) 2002-03-20 2010-03-10 Metabolex Inc SUBSTITUTED PHENYLACETIC ACIDS
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0226822D0 (en) 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
DE60323155D1 (de) 2002-12-19 2008-10-02 Scripps Research Inst Von transthyretin und zur hemmung von transthyretin-fehlfaltung
WO2004063155A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
EP1587798A4 (en) 2003-01-14 2007-06-27 Merck & Co Inc NSAID DERIVATIVES WITH GEMINAL DISUBSTITUTION AS ABETA REDUCING AGENTS 42
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
BRPI0408274B8 (pt) * 2003-03-14 2021-05-25 Univ Pittsburgh compostos de ligação de amiloide e composição farmacêutica
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
JP2006521357A (ja) 2003-03-24 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
JP2004302049A (ja) 2003-03-31 2004-10-28 Hodogaya Chem Co Ltd 感光性樹脂組成物
JP2006522130A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
JP3687660B2 (ja) 2003-04-22 2005-08-24 松下電工株式会社 マッサージ機
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
CN101198598A (zh) * 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法

Also Published As

Publication number Publication date
US20050261365A1 (en) 2005-11-24
EP1755585A4 (en) 2009-04-01
CN101198598A (zh) 2008-06-11
MXPA06013381A (es) 2007-03-01
RU2006145074A (ru) 2008-06-27
WO2005112913A1 (en) 2005-12-01
AU2005244999A1 (en) 2005-12-01
KR20070032700A (ko) 2007-03-22
WO2005112913B1 (en) 2006-02-09
JP2007538103A (ja) 2007-12-27
EP1755585A1 (en) 2007-02-28
WO2005113523A1 (en) 2005-12-01
US20080319175A1 (en) 2008-12-25
ZA200610417B (en) 2008-02-27
CA2566688A1 (en) 2005-12-01
US8338459B2 (en) 2012-12-25
KR20070013335A (ko) 2007-01-30
US20050272704A1 (en) 2005-12-08
BRPI0510033A (pt) 2007-10-02
EP1768968A1 (en) 2007-04-04
AU2005245470A1 (en) 2005-12-01
EP2314584A1 (en) 2011-04-27
WO2005118511A2 (en) 2005-12-15
US20110092545A1 (en) 2011-04-21
JP2007538095A (ja) 2007-12-27
CN1976693A (zh) 2007-06-06
US20050282780A1 (en) 2005-12-22
US7868033B2 (en) 2011-01-11
RU2371440C2 (ru) 2009-10-27
CA2566923A1 (en) 2005-12-01
WO2005118511A3 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
BRPI0510142A (pt) compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
CR20140544A (es) Compuestos para inhibir la progresión mitotica
CL2008003366A1 (es) Compuestos derivados de heterociclos nitrogenados fusionados, inhibidores de proteinas quinasas mek y mapk/erk; proceso de preparacion de los compuestos; composicion farmaceutica que los comprende; conjunto que los comprende; y su uso en la preparacion de medicamentos para el tratamiento de trastornos hiperproliferativos.
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
NO20081636L (no) FAP - inhibitorer
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
ECSP099525A (es) Inhibidores de mek
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
BRPI0510777A (pt) indazóis substituìdos, composições que os contêm, processo de produção e utilização
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
BRPI0606587A2 (pt) uso de metilnaltrexona e compostos correlatos para tratar disfunção gastrintestinal pós-operatória
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
BRPI0820967A2 (pt) Uso de uma composição, composição farmacêutica e método para tratamento, melhora ou profilaxia dos sintomas de uma doença inflamatória
CY1117184T1 (el) ΤΕΛΕΣΤΕΣ β-ΑΡΡΕΣΤΙΝΗΣ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΚΑΙ ΜΕΘΟΔΟΙΧΡΗΣΗΣ ΑΥΤΩΝ
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
BRPI0817319A2 (pt) Composto, composição farmacêutica, e, método para tratamento ou profilaxia de uma doença ou condição ou um ou mais sintomas da mesma.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
BRPI0607003A2 (pt) forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.